\-\ Texto\\:\\ \ \(0\)\
\-\ peripheral\\ blood\\ smear\\ had\\ elevated\\ eosinophils\\ at\\ 19\\.4\\%\\.\ \(0\)\
\-\ systemic\\ corticosteroids\\ are\\ the\\ mainstay\\ of\\ treatment\\.\\ \\ 70\\%\\ of\\ patients\\ usually\\ have\\ improvement\\ in\\ radiographic\\ findings\\ within\\ 1\\ week\\ of\\ starting\\ steroids\\.\ \(0\)\
\-\ the\\ axial\\ ct\\ images\\ show\\ primarily\\ peripheral\\ and\\ nonsegmental\\ areas\\ of\\ consolidation\\ primarily\\ involving\\ the\\ upper\\ lobes\\.\\ \\ the\\ superior\\ segments\\ of\\ the\\ lower\\ lobes\\ show\\ some\\ areas\\ of\\ peripheral\\ consolidation\\ as\\ well\\;\\ however\\,\\ the\\ basal\\ segments\\ are\\ spared\\.\\ \\ some\\ scattered\\ tree\\ and\\ bud\\ opacities\\ with\\ surrounding\\ ground\\ glass\\ opacities\\ and\\ sub\\ pleural\\ linear\\ and\\ reticular\\ opacities\\ are\\ visualized\\;\\ however\\,\\ the\\ dominant\\ pattern\\ is\\ that\\ of\\ peripheral\\ consolidation\\.\ \(0\)\
\-\ chronic\\ eosinophilic\\ pneumonia\ \(2\)\
\-\ cryptogenic\\ organizing\\ pneumonia\\ \\(cop\\,\\ boop\\)\ \(0\)\
\-\ chronic\\ eosinophilic\\ pneumonia\ \(2\)\
\-\ lipoid\\ pneumonia\ \(2\)\
\-\ bronchioloalveolar\\ cell\\ carcinoma\ \(0\)\
\-\ lymphoma\ \(373\)\
\-\ infection\\,\\ edema\\,\\ ards\\,\\ acute\\ interstitial\\ pneumonia\ \(0\)\
\-\ the\\ patient\\ presented\\ with\\ a\\ persistent\\ cough\\ and\\ chronic\\ infectious\\ symptoms\\ for\\ over\\ 5\\ months\\.\ \(0\)\
\-\ this\\ patient\\ was\\ a\\ middle\\ aged\\ female\\ who\\ presented\\ with\\ the\\ typical\\ symptoms\\ of\\ eosinophilic\\ pneumonia\\.\\ \\ the\\ peripheral\\ eosinophilia\\ and\\ radiographic\\ findings\\ further\\ supported\\ the\\ diagnosis\\ for\\ this\\ classic\\ case\\ of\\ chronic\\ eosinophilic\\ pneumonia\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ pneumonia\\:\\ 0\\.13013790982420825\ \(0\)\
\-\ eosinophilic\\:\\ 0\\.0964507772498787\ \(0\)\
\-\ peripheral\\:\\ 0\\.08136666636879256\ \(0\)\
\-\ opacities\\:\\ 0\\.07040225679910905\ \(0\)\
\-\ consolidation\\:\\ 0\\.06762503574968277\ \(0\)\
\-\ chronic\\:\\ 0\\.05067346595593684\ \(0\)\
\-\ segments\\:\\ 0\\.05061247619720029\ \(0\)\
\-\ primarily\\:\\ 0\\.0472082640387386\ \(0\)\
\-\ nonsegmental\\:\\ 0\\.04639746538929736\ \(0\)\
\-\ 19\\.4\\:\\ 0\\.04061529544893888\ \(0\)\
\-\ cop\\:\\ 0\\.04061529544893888\ \(0\)\
\-\ lobes\\:\\ 0\\.03963855175491538\ \(0\)\
\-\ cryptogenic\\:\\ 0\\.03910117927814004\ \(0\)\
\-\ boop\\:\\ 0\\.03910117927814004\ \(0\)\
\-\ lipoid\\:\\ 0\\.03910117927814004\ \(0\)\
\-\ bud\\:\\ 0\\.03792673953438104\ \(0\)\
\-\ bronchioloalveolar\\:\\ 0\\.03792673953438104\ \(0\)\
\-\ mainstay\\:\\ 0\\.03545303622256138\ \(0\)\
\-\ eosinophilia\\:\\ 0\\.03545303622256138\ \(0\)\
\-\ organizing\\:\\ 0\\.03483312550858041\ \(0\)\
\-\ radiographic\\:\\ 0\\.03414067780830246\ \(0\)\
\-\ sub\\:\\ 0\\.03377696395351646\ \(0\)\
\-\ ards\\:\\ 0\\.03331900933778156\ \(0\)\
\-\ smear\\:\\ 0\\.03250768997026968\ \(0\)\
\-\ eosinophils\\:\\ 0\\.032144569594022565\ \(0\)\
\-\ spared\\:\\ 0\\.030630453423223722\ \(0\)\
\-\ areas\\:\\ 0\\.030266812328905966\ \(0\)\
\-\ supported\\:\\ 0\\.0301288208979378\ \(0\)\
\-\ aged\\:\\ 0\\.029670866282202904\ \(0\)\
\-\ reticular\\:\\ 0\\.029249588873394818\ \(0\)\
\-\ starting\\:\\ 0\\.028674855757789598\ \(0\)\
\-\ show\\:\\ 0\\.0276121677314908\ \(0\)\
\-\ corticosteroids\\:\\ 0\\.02739263427011723\ \(0\)\
\-\ some\\:\\ 0\\.027315034251229043\ \(0\)\
\-\ tree\\:\\ 0\\.026725520029911208\ \(0\)\
\-\ glass\\:\\ 0\\.02602272322662425\ \(0\)\
\-\ however\\:\\ 0\\.02504597953260074\ \(0\)\
\-\ ground\\:\\ 0\\.024761287156806245\ \(0\)\
\-\ presented\\:\\ 0\\.024519554052867466\ \(0\)\
\-\ dominant\\:\\ 0\\.022953532251121\ \(0\)\
\-\ symptoms\\:\\ 0\\.02241744712524357\ \(0\)\
\-\ interstitial\\:\\ 0\\.022004154924930856\ \(0\)\
\-\ 70\\:\\ 0\\.021610464329758758\ \(0\)\
\-\ systemic\\:\\ 0\\.021516476869758723\ \(0\)\
\-\ \\;\\:\\ 0\\.02132022303634309\ \(0\)\
\-\ steroids\\:\\ 0\\.021156462517735564\ \(0\)\
\-\ improvement\\:\\ 0\\.020985287824548407\ \(0\)\
\-\ \\%\\:\\ 0\\.02098232666680008\ \(0\)\
\-\ scattered\\:\\ 0\\.02094335008955274\ \(0\)\
\-\ basal\\:\\ 0\\.020502828937570387\ \(0\)\
\-\ infectious\\:\\ 0\\.019336078249809673\ \(0\)\
\-\ findings\\:\\ 0\\.019145651955683785\ \(0\)\
\-\ linear\\:\\ 0\\.019066113542506778\ \(0\)\
\-\ are\\:\\ 0\\.018392745355730555\ \(0\)\
\-\ visualized\\:\\ 0\\.018204906048918345\ \(0\)\
\-\ typical\\:\\ 0\\.01803392996921051\ \(0\)\
\-\ persistent\\:\\ 0\\.01793866659213884\ \(0\)\
\-\ pleural\\:\\ 0\\.017465001045648926\ \(0\)\
\-\ cough\\:\\ 0\\.017232920414779328\ \(0\)\
\-\ classic\\:\\ 0\\.017232920414779328\ \(0\)\
\-\ pattern\\:\\ 0\\.017191801784585674\ \(0\)\
\-\ middle\\:\\ 0\\.016448205103381252\ \(0\)\
\-\ involving\\:\\ 0\\.01578109086317523\ \(0\)\
\-\ week\\:\\ 0\\.015273765359622252\ \(0\)\
\-\ elevated\\:\\ 0\\.015259559796626647\ \(0\)\
\-\ surrounding\\:\\ 0\\.014785080338761922\ \(0\)\
\-\ superior\\:\\ 0\\.014361808931864164\ \(0\)\
\-\ further\\:\\ 0\\.014302337588422412\ \(0\)\
\-\ usually\\:\\ 0\\.013657517125614521\ \(0\)\
\-\ 5\\:\\ 0\\.013158739065495596\ \(0\)\
\-\ infection\\:\\ 0\\.013073771442488459\ \(0\)\
\-\ lymphoma\\:\\ 0\\.012853677023102555\ \(0\)\
\-\ axial\\:\\ 0\\.012835744610883534\ \(0\)\
\-\ carcinoma\\:\\ 0\\.012746987736925612\ \(0\)\
\-\ edema\\:\\ 0\\.012720649944375214\ \(0\)\
\-\ months\\:\\ 0\\.012283901551000355\ \(0\)\
\-\ blood\\:\\ 0\\.012275847750048944\ \(0\)\
\-\ cell\\:\\ 0\\.012148635324113085\ \(0\)\
\-\ who\\:\\ 0\\.01172614952179843\ \(0\)\
\-\ patients\\:\\ 0\\.011639866312452767\ \(0\)\
\-\ over\\:\\ 0\\.011450750474420856\ \(0\)\
\-\ acute\\:\\ 0\\.011104628047928921\ \(0\)\
\-\ upper\\:\\ 0\\.010853055291414306\ \(0\)\
\-\ 1\\:\\ 0\\.01070171772610372\ \(0\)\
\-\ diagnosis\\:\\ 0\\.01032747016200221\ \(0\)\
\-\ well\\:\\ 0\\.010174110278782374\ \(0\)\
\-\ this\\:\\ 0\\.010117233824359294\ \(0\)\
\-\ lower\\:\\ 0\\.010115063522967697\ \(0\)\
\-\ case\\:\\ 0\\.009839497015090898\ \(0\)\
\-\ have\\:\\ 0\\.009739147780868904\ \(0\)\
\-\ had\\:\\ 0\\.009704472732845833\ \(0\)\
\-\ female\\:\\ 0\\.009246106691830703\ \(0\)\
\-\ treatment\\:\\ 0\\.009103247155794142\ \(0\)\
\-\ patient\\:\\ 0\\.009016757167540926\ \(0\)\
\-\ images\\:\\ 0\\.008627704694470285\ \(0\)\
\-\ within\\:\\ 0\\.008579638991505692\ \(0\)\
\-\ \\,\\:\\ 0\\.008548738911072233\ \(0\)\
\-\ the\\:\\ 0\\.008003905956525705\ \(0\)\
\-\ that\\:\\ 0\\.007768319623993807\ \(0\)\
\-\ for\\:\\ 0\\.007674822617291738\ \(0\)\
\-\ as\\:\\ 0\\.006803039504705935\ \(0\)\
\-\ ct\\:\\ 0\\.006291071859958121\ \(0\)\
\-\ at\\:\\ 0\\.006093490278061226\ \(0\)\
\-\ and\\:\\ 0\\.005684494917859531\ \(0\)\
\-\ of\\:\\ 0\\.005518601090431031\ \(0\)\
\-\ was\\:\\ 0\\.005201460643229931\ \(0\)\
\-\ a\\:\\ 0\\.004174734755985276\ \(0\)\
\-\ \\(\\:\\ 0\\.0038019038223361078\ \(0\)\
\-\ \\)\\:\\ 0\\.0037554615374384478\ \(0\)\
\-\ is\\:\\ 0\\.0029594251493932928\ \(0\)\
\-\ in\\:\\ 0\\.002217880158632921\ \(0\)\
\-\ with\\:\\ 0\\.0018474343593140486\ \(0\)\
\-\ \\.\\:\\ 0\\.001681556973032192\ \(0\)\
